The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing demand for precision medicine and real-world evidence studies. North America leads the market, while Asia-Pacific is the fastest-growing region due to rising investment and research capacity. Key trends include AI-powered patient recruitment, remote monitoring, and greater outsourcing to contract research organizations. Strategic acquisitions and integrated technology platforms are enhancing trial efficiency and data management.
Jefferies downgraded Home Depot from Buy to Hold due to worries over minimal profit growth despite expected revenue rise in Q2. Customer transactions have declined for five quarters, indicating growth relies on bigger purchases, not more customers. M...
Historical data suggests that a $10,000 investment in the QQQ ETF could increase to approximately $66,000 over a decade. This highlights the potential long-term growth of technology-focused investments. Investors might consider this when planning the...
Fabrinet reported quarterly earnings with an EPS of $4.10 and revenue of $1.32 billion, exceeding analyst expectations and marking a 45% increase in revenue year-over-year. The company specializes in optical packaging and manufacturing for high-growt...
Nano-X Imaging Ltd. is set to report its Q3 earnings with analysts expecting a loss of $0.16 per share and revenues of $5.38 million. The company is currently dealing with multiple class-action lawsuits alleging securities law violations, which adds ...
Bally's Corporation's stock plunged 26.3% following a 'going concern' warning due to its $4.5 billion debt, signaling financial risks. Beyond Meat's shares dropped 13.66% after a 1-for-30 reverse stock split, a move that often alarms investors. The G...
